FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386871687> ?p ?o ?g. }

• W4386871687 abstract "Abstract Background Despite major progress in novel breast cancer therapeutic regimens, anthracycline-based chemotherapy (ANT) remains among the most effective therapies. Cardiotoxicity, one of the most severe adverse events of ANT, has been defined as a reduction in left ventricular ejection fraction (LVEF) or global longitudinal strain (GLS). However, the role of early diastolic dysfunction has been insufficiently researched. We aimed to determine if diastolic dysfunction could early diagnose and predict ANT cardiotoxicity. Methods Studies that reported on echocardiographic parameters of diastolic function before and at the end of ANT in breast cancer patients without cardiac disease were included. We evaluated parameter derived from pulsed wave Doppler interrogation of the mitral valve inflow (E/A ratio and mitral E-wave deceleration time (EDT)) and tissue Doppler (mean velocities of the mitral ring in the early diastole (E') and E/E' ratio). Results A total of 892 patients from 13 studies were included. E/A ratio was significantly reduced at the end of ANT (OR 2.34, 95% CI [1.49, 3.68], p&lt;0.001), while EDT was not significantly influenced (OR 0.74, 95% CI [0.50, 1.08], p=0.121). Tissue Doppler velocity of the mitral ring E' and the LV filling pressure analysed through E/E' ratio did not show significant changes after ANT (OR 2.32, 95% CI [0.94, 5.72], p=0.068, and OR 0.79, 95% CI [0.56, 1.12], p=0.197, respectively). A modest reduction in LVEF and global longitudinal strain (GLS) was observed at the end of the ANT therapy with a difference in means of 3.77% and −1.08%, respectively. Patients receiving ANT doses over 400 mg/m2 doxorubicin or epirubicin therapeutic equivalent doses showed a significant change in E/A and E' after the therapy. Cardioprotective therapy like carvedilol, nebivolol and spironolactone did not have a significant impact on the parameter of diastolic function. Conclusion ANT has a modest early impact on LV diastolic function in patients with breast cancer without cardiac disease and cannot be validated as an early diagnostic or prognostic tool of ANT-induced cardiotoxicity. Randomized studies on larger population, using new parameter e.g. left atrial function parameter and multimodality imaging are required. Funding Acknowledgement Type of funding sources: None." @default.
• W4386871687 created "2023-09-20" @default.
• W4386871687 creator A5006252351 @default.
• W4386871687 creator A5057750459 @default.
• W4386871687 creator A5061494282 @default.
• W4386871687 creator A5084655624 @default.
• W4386871687 date "2021-10-01" @default.
• W4386871687 modified "2023-09-27" @default.
• W4386871687 title "Left ventricular diastolic function in patients with breast cancer treated with anthracycline-based chemotherapy" @default.
• W4386871687 doi "https://doi.org/10.1093/eurheartj/ehab724.2843" @default.
• W4386871687 hasPublicationYear "2021" @default.
• W4386871687 type Work @default.
• W4386871687 citedByCount "0" @default.
• W4386871687 crossrefType "journal-article" @default.
• W4386871687 hasAuthorship W4386871687A5006252351 @default.
• W4386871687 hasAuthorship W4386871687A5057750459 @default.
• W4386871687 hasAuthorship W4386871687A5061494282 @default.
• W4386871687 hasAuthorship W4386871687A5084655624 @default.
• W4386871687 hasBestOaLocation W43868716871 @default.
• W4386871687 hasConcept C121608353 @default.
• W4386871687 hasConcept C126322002 @default.
• W4386871687 hasConcept C164705383 @default.
• W4386871687 hasConcept C2776694085 @default.
• W4386871687 hasConcept C2776802502 @default.
• W4386871687 hasConcept C2777543888 @default.
• W4386871687 hasConcept C2778198053 @default.
• W4386871687 hasConcept C2778233292 @default.
• W4386871687 hasConcept C2780346441 @default.
• W4386871687 hasConcept C530470458 @default.
• W4386871687 hasConcept C57900726 @default.
• W4386871687 hasConcept C71924100 @default.
• W4386871687 hasConcept C78085059 @default.
• W4386871687 hasConcept C84393581 @default.
• W4386871687 hasConceptScore W4386871687C121608353 @default.
• W4386871687 hasConceptScore W4386871687C126322002 @default.
• W4386871687 hasConceptScore W4386871687C164705383 @default.
• W4386871687 hasConceptScore W4386871687C2776694085 @default.
• W4386871687 hasConceptScore W4386871687C2776802502 @default.
• W4386871687 hasConceptScore W4386871687C2777543888 @default.
• W4386871687 hasConceptScore W4386871687C2778198053 @default.
• W4386871687 hasConceptScore W4386871687C2778233292 @default.
• W4386871687 hasConceptScore W4386871687C2780346441 @default.
• W4386871687 hasConceptScore W4386871687C530470458 @default.
• W4386871687 hasConceptScore W4386871687C57900726 @default.
• W4386871687 hasConceptScore W4386871687C71924100 @default.
• W4386871687 hasConceptScore W4386871687C78085059 @default.
• W4386871687 hasConceptScore W4386871687C84393581 @default.
• W4386871687 hasIssue "Supplement_1" @default.
• W4386871687 hasLocation W43868716871 @default.
• W4386871687 hasOpenAccess W4386871687 @default.
• W4386871687 hasPrimaryLocation W43868716871 @default.
• W4386871687 hasRelatedWork W1949634191 @default.
• W4386871687 hasRelatedWork W1964205598 @default.
• W4386871687 hasRelatedWork W1998700507 @default.
• W4386871687 hasRelatedWork W2066491496 @default.
• W4386871687 hasRelatedWork W2392516189 @default.
• W4386871687 hasRelatedWork W2412833977 @default.
• W4386871687 hasRelatedWork W2475222081 @default.
• W4386871687 hasRelatedWork W2965474825 @default.
• W4386871687 hasRelatedWork W2974733069 @default.
• W4386871687 hasRelatedWork W3030454118 @default.
• W4386871687 hasVolume "42" @default.
• W4386871687 isParatext "false" @default.
• W4386871687 isRetracted "false" @default.
• W4386871687 workType "article" @default.